Case Reports in Gastrointestinal Medicine (Jan 2020)

Increased Risk of Liver Cirrhosis during Azathioprine Therapy for Crohn’s Disease

  • Jenny Roselli,
  • Tommaso Innocenti,
  • Erica Nicola Lynch,
  • Laura Parisio,
  • Giuseppe Macrì,
  • Monica Milla,
  • Tommaso Mello,
  • Andrea Galli,
  • Stefano Milani,
  • Mirko Tarocchi

DOI
https://doi.org/10.1155/2020/6726384
Journal volume & issue
Vol. 2020

Abstract

Read online

Azathioprine is a cornerstone of the therapy of Crohn’s disease. Unfortunately, infections and malignancies are relatively common adverse effects related to this drug; however, cirrhosis is exceptionally reported as a side effect. We report the case of a 49-year-old male patient with ileocolonic steno-penetrating Crohn’s disease who developed hepatic cirrhosis while treated with azathioprine. After taking azathioprine for 3 years with regular follow-up, he developed pancytopenia, and liver cirrhosis was diagnosed with ultrasound, abdomen computed tomography scan, transient elastography, and liver biopsy. As all other causes of liver damage were excluded, azathioprine was believed to be the cause of liver injury and therefore was interrupted.